Latest Breaking News On - Tokai university school - Page 6 : comparemela.com

April 27, 2021 SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/  DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of chronic low back pain. Injectable Disc Cell Therapy (IDCT) is a non-surgical study treatment for lumbar disc degeneration. This Japanese 38-subject trial is being conducted at seven sites across the Country and passed the first of two planned mid-trial safety reviews by an Independent Data Monitoring Committee (IDMC). All treated subjects will be observed and evaluated for safety, primary efficacy, and secondary outcome measures for a period of six months, at which time another IDMC review will be completed. Per the study

Daisuke sakaiFlagg flanaganDiscgenics incDrug administrationData monitoring committeeDevices agencyDiscogenic cellDisc cell therapyIndependent data monitoring committeeAssociate professorOrthopaedic surgeryTokai university schoolDiscogenic cellsClinical trial notificationMedical devices agencyBiologics evaluation